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Introduction
Hypothyroidism is a common endocrine disorder of 
dogs, with an estimated prevalence of 0.2% (Panciera, 
1994). Central hypothyroidism reportedly accounts for 
less than 5% of these cases (Feldman and Nelson, 2004), 
and is theoretically caused by decreased thyroidal T4 and 
T3 production due to a reduction in pituitary thyroid 
stimulating hormone (cTSH) (secondary hypothyroidism) 
or hypothalamic thyrotropin releasing hormone (TRH) 
(tertiary hypothyroidism) secretion.  
Central hypothyroidism is most commonly associated 
with congenital disorders affecting the pituitary gland 
(Eigenmann, 1981; Greco et al., 1991; Mooney and 
Anderson, 1993; Hamann et al., 1999; Kooistra et al., 2000). 
Central hypothyroidism has also been reported in dogs in 
association with neoplasia (Neer and Reavis, 1983; Barr, 
1985; Hare, 1993), however, a definitive diagnosis was 
not achieved in all cases, and attempts were not made to 
differentiate between secondary and tertiary disease. This 
case report is the first confirmed case of canine tertiary 
hypothyroidism.  
Case history
A nine-year-old entire male Labrador, weighing 48.2kg, 
was examined at the University Veterinary Hospital 
(UVH), University College Dublin for the investigation 
of polyuria, polydipsia and polyphagia of several months’ 
duration. Coat quality was poor, with mild generalised 
seborrhoea, patchy alopecia and thinning with loss 
of elasticity of the ventral abdominal skin. Moderate 
abdominal distension was present.  
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A nine-year-old male entire Labrador was diagnosed with pituitary dependent hyperadrenocorticism. Following seven 
months of successful mitotane therapy, the dog presented with marked weight gain, seborrhoea and alopecia. Routine 
clinicopathological analyses revealed marked hypercholesterolaemia. Serum total and free thyroxine (T4) concentrations 
were below their respective reference ranges. Serum thyroid stimulating hormone (cTSH) concentration was within 
reference range. TSH and thyrotropin releasing hormone (TRH) response tests revealed adequate stimulation of total 
T4 in both, and cTSH in the latter test. Magnetic resonance imaging revealed a mass arising from the pituitary fossa, 
with suprasellar extension. A diagnosis of tertiary hypothyroidism was made. Following four weeks of levothyroxine 
therapy, circulating cholesterol concentration had declined, weight loss had ensued and dermatological abnormalities had 
improved. Euthanasia was performed four months later due to the development of neurological signs. A highly infiltrative 
pituitary adenoma, with effacement of the overlying hypothalamus was identified on post mortem examination. Tertiary 
hypothyroidism has not been previously reported in dogs.
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Parameter Initial 
presentation
Seven months later (pre-
levothyroxine treatment)
Ten months later       




(at time of 
euthanasia)
Reference range
Alkaline phosphatase (iu/L)  1065 360 338 185 5-50
Alanine aminotransferase (iu/L)   255   31   23   12 5-20
Creatine kinase (iu/L)     73   59   59   21 0-50
Cholesterol (mmol/L)    13.2   15     6.4     6.7 3.2-6.5
Table 1: Routine clinicopathological findings
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Routine clinicopathological analyses revealed lymphopenia 
and eosinopenia with elevated alkaline phosphatase 
(AP), alanine aminotransferase (ALT), creatine kinase 
(CK) and cholesterol concentrations (Table 1). Urinalysis 
revealed hyposthenuria (specific gravity 1.005). Results of 
adrenocorticotropic hormone (ACTH) response and low 
dose dexamethasone suppression tests were supportive 
of hyperadrenocorticism (Table 2). Two similarly sized 
adrenal glands [caudal pole width of 12.9 mm (left) and 
10.7mm (right)] identified ultrasonographically together 
with elevated plasma endogenous ACTH concentration 
confirmed pituitary dependent hyperadrenocorticism 
(Table 2).  
Treatment with mitotane at 50mg/kg p.o. once daily 
resulted in adequate control after five days of treatment (as 
determined by repeat ACTH response testing and reduced 
water intake), and once weekly maintenance therapy at the 
above dose was commenced.  Prednisolone (0.2 mg/kg p.o. 
once daily) was also prescribed, to be given only if clinical 
signs of hypocortisolaemia developed. ACTH stimulation 
testing confirmed adequate control one and three months 
after commencing maintenance therapy (Table 2).  
The dog was re-examined at the UVH seven months 
following the initial diagnosis of hyperadrenocorticism. 
There had been significant weight gain (weight 55.7kg). 
Lethargy and dullness had also developed and, despite 
initial improvement, the coat quality had deteriorated with 
extensive seborrhoea and alopecia. Polyuria, polydipsia 
and polyphagia had not been observed. Prednisolone, at 
the above replacement dose, had been administered by 
the owner over one week, but was discontinued when no 
improvement was noted.  
Routine clinicopathological tests were repeated and 
amarked hypercholesterolaemia was detected (Table 1). 
An ACTH stimulation test showed adequate control of 
hyperadrenocorticism (Table 2).  Basal serum total and 
free thyroxine (T4) values were below their respective 
reference ranges (Table 3). Serum cTSH concentration 
was within the lower end of the reference range (Table 
3).  A TSH stimulation test was performed using 75μg 
of intravenous recombinant human TSH (Thyrogen, 
Genzyme corporation) (Sauvé and Paradis, 2000; Roover et 
al., 2003) and revealed an adequate rise in concentration of 
total T4 after six hours (Table 3). A TRH response test was 
subsequently performed using 200μg of TRH (Protirelin, 
Cambridge Labs, Cambridge, UK) (Scott-Moncrieff and 
Nelson, 1998) and revealed a substantial elevation in cTSH 
concentration after 30 minutes and an adequate increase 
in total T4 after four hours (Table 3). Magnetic resonance 
Table 3: Thyroid function test results
PARAMETER Result Reference range
Basal total T4 (nmol/L) <6.435  15 0- 50 
Basal cTSH (ng/mL) 0.1 < 0.68 
Free T4 (pmol/L) 4.0  6.6 - 40 
TSH response test See below
Basal total T4 9.9
4 hour total T4 29.3
TRH response test See below
Basal total T4 12.1
Basal cTSH 0.07
30 minute cTSH 0.56
4 hour total T4 23.9
Monitoring treatment
1 month total T4 51.2 > 35 nmol/L
1 month cTSH < 0.03
TSH response test
A post TSH total T4 concentration above 25 nmol/L, and a greater than 1.5 fold 
increase over basal concentrations, precludes primary hypothyroidism (Dixon and 
Mooney, 1999).  
TRH response test
A post TRH total T4 concentration greater than 6 nmol/L over the basal 
concentration, and a greater than 1.5 fold increase over the basal concentration, makes 
both primary and secondary hypothyroidism unlikely (Panciera, 1998).
Table 2: Adrenal function test results
Test Result Reference range
Initial diagnosis
ACTH stimulation test Pre-ACTH cortisol 163 nmol/L
Post-ACTH cortisol 968 nmol/L <450 nmol/L 
Low dose dexamethasone suppression test Basal sample 229 nmol/L
3 hour sample 155 nmol/L
8 hour sample 331nmol/L < 30 nmol/L
Endogenous ACTH 119 pg/mL 20-80 pg/mL
Monitoring therapy
ACTH stimulation test (after 5 days induction)  Pre-ACTH cortisol   34.3 nmol/L
Post-ACTH cortisol   58.2 nmol/L <120 nmol/L
ACTH stimulation test (1 month) Pre-ACTH cortisol <27.59 nmol/L
Post-ACTH cortisol   67.7 nmol/L <120 nmol/L
ACTH stimulation test (3 months) Pre-ACTH cortisol   41.5 nmol/L
Post-ACTH cortisol   96.4 nmol/L <120 nmol/L
ACTH stimulation test (7 months) Pre-ACTH cortisol   53.5 nmol/L
Post-ACTH cortisol  102 nmol/L <120 nmol/L 
ACTH = Adrenocorticotropic hormone
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imaging (MRI) revealed a roughly bilobed, 2x2x3cm 
mass arising from the pituitary fossa, showing suprasellar 
extension dorsally and rostrally, with a marked mass effect 
on neighbouring structures (Figures 1 and 2).  
A diagnosis of tertiary hypothyroidism was made, and 
treatment with levothyroxine commenced (0.8 mg p.o. 
once daily). When the dog was re-examined four weeks 
later, seborrhoea was less marked and hair regrowth had 
commenced. The owner reported improved demeanour 
and exercise tolerance and body weight had reduced to 
52.5kg.  Cholesterol had reduced to within reference 
range (Table 1) and serum total T4 confirmed adequate 
replacement therapy (Table 3) (Dixon et al., 2002). 
Two months following commencement of treatment of 
hypothyroidism, the dermatological changes had further 
improved but dullness, depression, head pressing and 
mild ataxia had developed. Neurological examination was 
otherwise unremarkable. Prednisolone was commenced 
at a high dose (2mg/kg/day), but resulted in only short 
term, partial improvement. Euthanasia was performed two 
months later due to progression of the neurological signs.  
Post mortem examination revealed the presence of a highly 
infiltrative pituitary adenoma with effacement of the 
overlying hypothalamus (Figure 3). Pituitary histopathology 
revealed a dense aggregate of pleomorphic cells of cuboidal 
to polygonal outline with eosinophilic cytoplasm and ovoid, 
frequently hyperchromatic nuclei. Tumour cells were 
noted pallisading around blood vessels. Rare attempts at 
acinar formation were observed. Multinucleated cells and 
karyomegaly were features and one mitotic figure per high 
power field was counted (Figure 4). A small amount of 
compressed pituitary tissue was identified grossly but was 
not apparent on histopathology sections.The thyroid gland 
was grossly reduced in size. Histopathologically, there was 
a large percentage of small diameter follicles containing 
clumped or little colloid with no evidence of inflammatory 
cell infiltration. The corticomedullary junction of both 
adrenal glands was irregular with a cortical-medullary 
ratio of 1:1. Histopathology revealed cortical atrophy with 
hyperplastic nodules and foci of mineralisation within the 
cortex.  
Discussion
Central hypothyroidism is rare in humans, estimated to 
occur in 0.005% of the general population (Martino and 
Pinchero, 2005). Most cases are associated with congenital 
defects, however various acquired structural and functional 
disorders have also been described. Congenital defects also 
appear to be the most common cause of canine central 
hypothyroidism. Spontaneous central hypothyroidism 
has rarely been reliably diagnosed in adult dogs, and 
differentiation into secondary and tertiary disease was not 
attempted in reported cases. 
Lethargy, dullness, weight gain, seborrhoea and 
alopecia were present in this case; features consistent 
with a diagnosis of hypothyroidism (Dixon et al., 1999). 
Lethargy and dullness may be associated with pituitary 
macrotumours, but this was thought unlikely due to lack 
of other neurological signs and complete resolution of these 
signs following T4 replacement therapy. The improved 
demeanour and dermatological features, increased exercise 
tolerance and weight loss following treatment are further 
supportive of hypothyroidism. Some dermatological 
abnormalities had not fully resolved after initiation of 
treatment, but it can take up to six months before full 
improvement is noted (Dixon et al., 2002; Dixon, 2004). 
The neurological signs observed terminally in this case 
were more likely due to tumour expansion rather than 
hypothyroidism, as replacement therapy was adequate, and 
the other clinical signs of hypothyroidism were improving 
at the time of development.  
The elevated cholesterol and creatine kinase concentrations 
were consistent with hypothyroidism (Dixon et al., 1999). 
Other causes of marked hypercholesterolaemia, including 
excessive endogenous (uncontrolled hyperadrenocorticism) 
or exogenous glucocorticoids, diabetes mellitus, cholestasis, 
nephrotic syndrome and primary hyperlipidaemia 
and hypercholesterolaemia, were excluded during 
the investigation, or would not have improved with 
levothyroxine treatment alone. Hyperadrenocorticism had 
been adequately controlled for several months at the time 
of investigation of hypothyroidism.  Prednisolone had been 
prescribed, but replacement dosages are unlikely to induce 
Figure 1: 
Sagittal T1 weighted post 
contrast image of the brain, 
showing a homogeneously 
enhancing, irregularly 
marginated mass of 2cm in 
diameter in the pituitary 
fossa (indicated with 
arrow). The mass extends 
dorsally and rostrally.
Figure 2: 
Transverse T1 weighted 
post contrast image of the 
brain. The hyperintense 
mass in the ‘sella turcica’ 
appears bilobed and mildly 
asymmetric, protruding 
slightly towards the left 
cerebral hemisphere 
(indicated with arrow).
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such marked hypercholesterolaemia and prednisolone had 
been discontinued three weeks preceding thyroid function 
testing (Dillon et al., 1980).  
Low serum total and free T4 concentrations were present 
in this dog.  Basal serum total and free T4 concentrations 
are invariably low in hypothyroidism, but both can also be 
suppressed by various non-thyroidal factors, including drug 
therapy and non-thyroidal illness. Prednisolone had been 
administered at replacement doses to this dog. Although 
immunosuppressive doses of prednisolone are associated 
with reduced total T4 concentrations, anti-inflammatory 
doses administered over one month do not have an effect 
on either total or free T4 concentrations (Torres et al., 1991; 
Moore et al., 1993). Non-thyroidal illness is commonly 
associated with reduced total T4 concentrations, but free T4 
concentrations are typically only suppressed by severe illness 
(Kantrowitz et al., 2001). No signs of severe non-thyroidal 
illness were present in this case and were also unlikely 
given the marked improvement with levothyroxine 
therapy alone. Only clinical signs consistent with 
hypothyroidism were exhibited. Hyperadrenocorticism 
is commonly associated with reduced free and total T4 
concentrations (Nelson et al., 1991; Ferguson and Peterson, 
1992). Although this disease was originally present, it was 
adequately controlled at the time of sampling (determined 
by ACTH response test and clinical signs) when both 
total and free T4 concentrations are expected to be within 
their respective reference ranges (Peterson et al., 1984). 
Therefore, these results are supportive of a diagnosis of 
hypothyroidism, but they do not differentiate between 
primary and central disease.  
The serum cTSH concentration was within reference 
range. Such a result would be expected in central 
hypothyroidism, and may occur in 20-30% of primary 
hypothyroidism cases consequent to pituitary exhaustion 
or production of cTSH isoforms not detected by the assay 
(Dixon, 2004). Concentrations of cTSH can be suppressed 
by concurrent drug administration or non-thyroidal illness, 
and it is possible that prednisolone lowered concentrations 
in this case. However, prednisolone was given for only 
one week at a replacement dose, and treatment with 30 
mg of prednisone for one week in human patients did not 
influence basal TSH concentration (Brabant et al., 1989). 
In humans, low TSH concentrations are commonly seen 
in patients with central hypothyroidism, but the current 
canine assay cannot distinguish between low and normal 
concentrations and, as a consequence, the presence of a 
reference range cTSH value can be consistent with central 
hypothyroidism. 
The post TSH total T4 concentration was above 25 nmol/L, 
and demonstrated a greater than 1.5 fold increase over basal 
concentrations, precluding primary hypothyroidism (Dixon 
and Mooney, 1999). This result could occur in central 
hypothyroidism or euthyroidism. Reduced T4 responses 
to TSH administration have been reported in animals 
with congenital and acquired secondary hypothyroidism 
(Greco et al., 1991; Mellanby et al., 2005), but this response 
is dependent on the duration of the disease and the severity 
of thyroid gland atrophy. As a consequence, normal 
stimulation following either single or repeated TSH 
administrations is possible with central hypothyroidism 
(Feldman and Nelson, 1987).  
The post TRH total T4 concentration demonstrated a 
greater than 1.5 fold increase, and greater than 6 nmol/L 
increase over the basal concentration, making both primary 
and secondary hypothyroidism unlikely (Panciera, 1998). 
The cTSH response to TRH administration was similar 
to that described in euthyroid dogs, also making secondary 
Figure 3:
Midline sagittal section of formalin-fixed brain revealing a 2 
cm diameter, well-demarcated mass (indicated with arrow) 
that is largely replacing the hypothalamus.
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hypothyroidism unlikely (Scott-Moncrieff and Nelson, 
1998). In humans, a reduced TSH response is expected 
in secondary and a normal or exaggerated response in 
tertiary hypothyroidism. Less commonly, absent and 
impaired responses have been recorded with hypothalamic 
disease, with only occasional patients with pituitary disease 
exhibiting a normal response (Martino and Pinchero, 2005). 
Therefore, these results are highly suggestive of tertiary 
hypothyroidism.
In humans, endogenous TRH can be assayed to attempt 
to differentiate secondary and tertiary hypothyroidism 
but, as most TRH in peripheral blood originates from 
extrahypothalamic sources, it cannot be reliably used to 
differentiate between the two conditions (Engler et al., 
1981; Martino and Pinchero, 2005). In addition, this assay 
has not been validated in the dog. 
In this case, a diagnosis of tertiary hypothyroidism was 
further supported by the destruction of hypothalamic tissue 
by the expanding pituitary mass, as evident on both MRI 
and post mortem examination. In theory, any expansive 
or infiltrative mass could affect hypothalamic TRH or 
pituitary TSH producing cells. It is likely in this case 
that the infiltrative adenoma was a functional pituitary 
macrotumour, responsible for the pituitary dependent 
hyperadrenocorticism earlier diagnosed. 
Other endocrinopathies were not detected, but 
hyposecretion of TSH as the sole demonstrable abnormality 
has been reported in humans in both acquired and 
congenital forms of secondary hypothyroidism, and similar 
monotropic deficiencies are theoretically possible within 
the hypothalamus (Larsen and Davies, 2003). Concurrent 
pituitary hormone deficiencies cannot be fully excluded 
because specific tests for other pituitary hormones were not 
performed but the lack of supportive clinical signs makes 
such deficiencies unlikely.  
The presence of the atrophic changes within the thyroid 
glands is consistent with levothyroxine administration. 
Similar changes are expected with central hypothyroidism, 
but biopsy prior to levothyroxine therapy would have 
been necessary to confirm this diagnosis. Such an invasive 
procedure was not considered justified.  However, there 
was no evidence of either lymphocytic thyroiditis or 
idiopathic thyroidal atrophy, thereby making primary 
hypothyroidism unlikely.  
In this case, progressive expansion and effacement of 
the overlying hypothalamus lead to the development of 
tertiary hypothyroidism, with sparing of TSH-producing 
cells within the pituitary gland, as demonstrated by TRH 
stimulation test results. This case report confirms that 
tertiary hypothyroidism exists in dogs, albeit rarely.
Figure 4: Photomicrograph of neoplasm reveals a dense aggregate of pleomorphic cells of cuboidal to polygonal outline with eosinophilic cytoplasm and ovoid, frequently 
hyperchromatic, nuclei. Tumour cells are noted pallisading around blood vessels. Rare attempts at acinar formation are observed. Multinucleated cells and karyomegaly are 
features and one mitotic figure per high power field is counted. (Haematoxylin and Eosin; original magnification 40X).   
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